Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Require lipid-modifying therapy for primary or secondary prevention of cardiovascular disease~* Fasting LDL-C ≥ 130 mg/dL for primary prevention or LDL-C ≥ 100 mg/dL for secondary prevention (history of HeFH and/or ASCVD)~* Treated with maximally tolerated statin therapy at stable dose for at least 4 weeks prior to screening~Exclusion Criteria:~* Total Fasting Triglyceride ≥ 400 mg/dL~* Renal Dysfunction or nephrotic syndrome or history of nephritis~* Significant cardiovascular disease or cardiovascular event within the past 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BA 180 mg + EZE 10 mg FDC (Type: EXPERIMENTAL): Bempedoic acid (BA) + ezetimibe (EZE) fixed-dose combination (FDC) 180 mg/10 mg tablets taken orally once daily for 12 weeks
- BA 180 mg (Type: EXPERIMENTAL): Bempedoic acid (BA) 180 mg tablets taken orally once daily for 12 weeks
- EZE 10 mg (Type: ACTIVE_COMPARATOR): Ezetimibe (EZE) 10 mg overencapsulated tablets taken orally once daily for 12 weeks
- Placebos (Type: PLACEBO_COMPARATOR): Placebos to match identical bempedoic acid + ezetimibe fixed-dose combination (FDC) 180 mg/10 mg tablet, or identical bempedoic acid 180 mg tablet, or identical ezetimibe 10 mg capsule, taken orally, once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).